TY - JOUR
T1 - Structure of a D2 dopamine receptor–G-protein complex in a lipid membrane
AU - Yin, Jie
AU - Chen, Kuang Yui M.
AU - Clark, Mary J.
AU - Hijazi, Mahdi
AU - Kumari, Punita
AU - Bai, Xiao chen
AU - Sunahara, Roger K.
AU - Barth, Patrick
AU - Rosenbaum, Daniel M.
N1 - Funding Information:
Acknowledgements Cryo-EM data were collected at the University of Texas Southwestern Medical Center Cryo-EM Facility, which is funded by the CPRIT Core Facility Support Award RP170644. We thank E. Ross for providing plasmids for G-protein expression. This project was supported by the Edward Mallinckrodt, Jr. Foundation (Scholar Award to D.M.R.), the Welch Foundation (grant I-1770 to D.M.R. and grant I-1944-20180324 to X.-c.B.), the EPFL (to P.B.), the Swiss National Science Foundation (grant 31003A_182263 to P.B.), the Ludwig Institute for Cancer research (to P.B.), the Virginia Murchison Linthicum Scholar in Medical Research at University of Texas Southwestern (to X.-c.B.), CPRIT (RR160082 to X.-c.B.) and the US National Institutes of Health (R01-GM097207 to P.B. and R01-GM083118 to R.K.S.).
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/8/6
Y1 - 2020/8/6
N2 - The D2 dopamine receptor (DRD2) is a therapeutic target for Parkinson’s disease1 and antipsychotic drugs2. DRD2 is activated by the endogenous neurotransmitter dopamine and synthetic agonist drugs such as bromocriptine3, leading to stimulation of Gi and inhibition of adenylyl cyclase. Here we used cryo-electron microscopy to elucidate the structure of an agonist-bound activated DRD2–Gi complex reconstituted into a phospholipid membrane. The extracellular ligand-binding site of DRD2 is remodelled in response to agonist binding, with conformational changes in extracellular loop 2, transmembrane domain 5 (TM5), TM6 and TM7, propagating to opening of the intracellular Gi-binding site. The DRD2–Gi structure represents, to our knowledge, the first experimental model of a G-protein-coupled receptor–G-protein complex embedded in a phospholipid bilayer, which serves as a benchmark to validate the interactions seen in previous detergent-bound structures. The structure also reveals interactions that are unique to the membrane-embedded complex, including helix 8 burial in the inner leaflet, ordered lysine and arginine side chains in the membrane interfacial regions, and lipid anchoring of the G protein in the membrane. Our model of the activated DRD2 will help to inform the design of subtype-selective DRD2 ligands for multiple human central nervous system disorders.
AB - The D2 dopamine receptor (DRD2) is a therapeutic target for Parkinson’s disease1 and antipsychotic drugs2. DRD2 is activated by the endogenous neurotransmitter dopamine and synthetic agonist drugs such as bromocriptine3, leading to stimulation of Gi and inhibition of adenylyl cyclase. Here we used cryo-electron microscopy to elucidate the structure of an agonist-bound activated DRD2–Gi complex reconstituted into a phospholipid membrane. The extracellular ligand-binding site of DRD2 is remodelled in response to agonist binding, with conformational changes in extracellular loop 2, transmembrane domain 5 (TM5), TM6 and TM7, propagating to opening of the intracellular Gi-binding site. The DRD2–Gi structure represents, to our knowledge, the first experimental model of a G-protein-coupled receptor–G-protein complex embedded in a phospholipid bilayer, which serves as a benchmark to validate the interactions seen in previous detergent-bound structures. The structure also reveals interactions that are unique to the membrane-embedded complex, including helix 8 burial in the inner leaflet, ordered lysine and arginine side chains in the membrane interfacial regions, and lipid anchoring of the G protein in the membrane. Our model of the activated DRD2 will help to inform the design of subtype-selective DRD2 ligands for multiple human central nervous system disorders.
UR - http://www.scopus.com/inward/record.url?scp=85086257637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086257637&partnerID=8YFLogxK
U2 - 10.1038/s41586-020-2379-5
DO - 10.1038/s41586-020-2379-5
M3 - Article
C2 - 32528175
AN - SCOPUS:85086257637
SN - 0028-0836
VL - 584
SP - 125
EP - 129
JO - Nature
JF - Nature
IS - 7819
ER -